Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis

被引:47
作者
Banerjee, Souvik [1 ]
Hwang, Dong-Jin [1 ]
Li, Wei [1 ]
Miller, Duane D. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, 881 Madison Ave, Memphis, TN 38163 USA
关键词
tubulin dynamics; tubulin inhibitors; multidrug resistance; nanoparticle formulations; beta-tubulin isotypes and drug resistance; angiogenesis; vascular disrupting agent; antimitotic; PHASE-I TRIAL; SERUM-ALBUMIN NANOPARTICLES; ENDOTHELIAL-CELL MIGRATION; BOUND NAB PACLITAXEL; TESTING STAGE 1; TUMOR-VASCULATURE; TRASTUZUMAB-EMTANSINE; BIOLOGICAL EVALUATION; POLYMERIZATION INHIBITOR; ANTIANGIOGENIC ACTIVITY;
D O I
10.3390/molecules21111468
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extensive research over the last decade has resulted in a number of highly potent tubulin polymerization inhibitors acting either as microtubule stabilizing agents (MSAs) or microtubule destabilizing agents (MDAs). These inhibitors have potent cytotoxicity against a broad spectrum of human tumor cell lines. In addition to cytotoxicity, a number of these tubulin inhibitors have exhibited abilities to inhibit formation of new blood vessels as well as disrupt existing blood vessels. Tubulin inhibitors as a vascular disrupting agents (VDAs), mainly from the MDA family, induce rapid tumor vessel occlusion and massive tumor necrosis. Thus, tubulin inhibitors have become increasingly popular in the field of tumor vasculature. However, their pharmaceutical application is halted by a number of limitations including poor solubility and toxicity. Thus, recently, there has been considerable interests in the nanoparticle drug delivery of tubulin inhibitors to circumvent those limitations. This article reviews recent advances in nanoparticle based drug delivery for tubulin inhibitors as well as their tumor vasculature disruption properties.
引用
收藏
页数:19
相关论文
共 120 条
[71]   Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers [J].
Murray, Bryan C. ;
Peterson, Michael T. ;
Fecik, Robert A. .
NATURAL PRODUCT REPORTS, 2015, 32 (05) :654-662
[72]   Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins [J].
Nicolaou, K. C. ;
Yun, Jun ;
Mandal, Debashis ;
Erande, Rohan D. ;
Klahn, Philipp ;
Jin, Michael ;
Aujay, Monette ;
Sandoval, Joseph ;
Gavrilyuk, Julia ;
Vourloumis, Dionisios .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2016, 138 (05) :1698-1708
[73]   β-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand [J].
O'Boyle, Niamh M. ;
Pollock, Jade K. ;
Carr, Miriam ;
Knox, Andrew J. S. ;
Nathwani, Seema M. ;
Wang, Shu ;
Caboni, Laura ;
Zisterer, Daniela M. ;
Meegan, Mary J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (22) :9370-9382
[74]   Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors [J].
Oh, Do-Youn ;
Kim, Tae-Min ;
Han, Sae-Won ;
Shin, Dong-Yeop ;
Lee, Yun Gyoo ;
Lee, Keun-Wook ;
Kim, Jee Hyun ;
Kim, Tae-You ;
Jang, In-Jin ;
Lee, Jong-Seok ;
Bang, Yung-Jue .
CANCER RESEARCH AND TREATMENT, 2016, 48 (01) :28-36
[75]   Chromenes: potential new chemotherapeutic agents for cancer [J].
Patil, Shivaputra A. ;
Patil, Renukadevi ;
Pfeffer, Lawrence M. ;
Miller, Duane D. .
FUTURE MEDICINAL CHEMISTRY, 2013, 5 (14) :1647-1660
[76]   New substituted 4H-chromenes as anticancer agents [J].
Patil, Shivaputra A. ;
Wang, Jin ;
Li, Xiaochen S. ;
Chen, Jianjun ;
Jones, Terreia S. ;
Hosni-Ahmed, Amira ;
Patil, Renukadevi ;
Seibel, William L. ;
Li, Wei ;
Miller, Duane D. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (13) :4458-4461
[77]   Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance [J].
Perez, Edith A. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (08) :2086-2095
[78]   Pharmacokinetics of Fosamprenavir plus Ritonavir in Human Immunodeficiency Virus Type 1-Infected Adult Subjects with Hepatic Impairment [J].
Perez-Elias, Maria J. ;
Larrousse Morellon, Maria ;
Ortega, Enrique ;
Hernandez-Quero, Jose ;
Rodriguez-Torres, Maribel ;
Clotet, Bonaventura ;
Felizarta, Franco ;
Gutierrez, Felix ;
Pineda, Juan A. ;
Nichols, Garrett ;
Lou, Yu ;
Wire, Mary Beth .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (12) :5185-5196
[79]   Vascular disrupting agents [J].
Pilat, M. J. ;
LoRusso, Pa. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 99 (04) :1021-1039
[80]   Antibody Drug Conjugates for Cancer Therapy [J].
Polakis, Paul .
PHARMACOLOGICAL REVIEWS, 2016, 68 (01) :3-19